Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All povidone‑iodine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPVP-IPovidone-Iod.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

Anderson et al., Infectious Diseases and Therapy, doi:10.1007/s40121-020-00316-3
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PVP-I for COVID-19
12th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000004 from 21 studies.
Lower risk for mortality, cases, and viral clearance.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
In Vitro study showing rapid and effective virucidal activity of PVP-I against SARS-CoV-2. All four products tested [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved C 99.99% virucidal activity against SARS-CoV-2, corresponding to C 4 log10 reduction of virus titre, within 30s of contact.
9 preclinical studies support the efficacy of povidone-iodine for COVID-19:
Anderson et al., 8 Jul 2020, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperPovidone-Iod..All
Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease
Danielle E Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M Jenkins, Yacine Hadjiat, Maren Eggers
Infectious Diseases and Therapy, doi:10.1007/s40121-020-00316-3
Introduction: As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing [ 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. Methods: Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30 s for virucidal activity. Viral titres were calculated using the Spearman-Ka ¨rber method and reported as median tissue culture infectious dose (TCID 50 )/mL. Results: All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved C 99.99% virucidal activity against SARS-CoV-2, corresponding to C 4 log 10 reduction of virus titre, within 30 s of contact. Conclusion: This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.
References
Bai, Yao, Wei, Presumed asymptomatic carrier of COVID-19, JAMA
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, Features, evaluation and treatment coronavirus (COVID-19)
Chin, Chu, Perera, Stability of SARS-CoV-2 in different environmental conditions, Lancet Microbe
Comite ´europe ´en, ? A1:2015: Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements
Corman, Muth, Niemeyer, Drosten, Hosts and sources of endemic human coronaviruses, Adv Virus Res
Eggers, Eickmann, Zorn, Rapid and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA), Infect Dis Ther
Eggers, Koburger-Janssen, Eickmann, Zorn, In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens, Infect Dis Ther
Eggers, Koburger-Janssen, Ward, Newby, Mu ¨ller S, Bactericidal and virucidal activity of povidone-iodine and chlorhexidine gluconate cleansers in an in vivo hand hygiene clinical simulation study, Infect Dis Ther
Gui, Pepe, Magalini, Just one more hygiene practice in COVID-19, Eur Rev Med Pharmacol Sci
Kariwa, Fujii, Takashima, Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents, Dermatology
Kawana, Kitamura, Nakagomi, Inactivation of human viruses by povidone-iodine in comparison with other antiseptics, Dermatology
Kirk-Bayley, Challacombe, Sunkaraneni, Combes, The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers, doi:10.2139/ssrn.3563092
Mady, Kubik, Baddour, Snyderman, Rowan, Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as ''Personal Protective Equipment'' for frontline providers exposed in high-risk head and neck and skull base oncology care, Oral Oncol
Nagatake, Ahmed, Oishi, Prevention of respiratory lnfections by povidone-lodine gargle, Dermatology
O'donnell, Thomas, Stanton, Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection, Function
Sanche, Lin, Xu, Romero-Severson, Hengartner et al., High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2, Emerg Infect Dis
Spearman, The method of 'right and wrong cases' ('constant stimuli') without Gauss's formulae, Br J Psychol
To, Tsang, Leung, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis
Vogt, Hauser, Mueller, Bosse, Hopp, Efficacy of conventional and liposomal povidoneiodine in infected mesh skin grafts: an exploratory study, Infect Dis Ther
Wo ¨lfel, Corman, Guggemos, Virological assessment of hospitalized patients with COVID-2019, Nature
Zhao, Lin, Ran, Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak, Int J Infect Dis
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
¨rber, Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche, Archiv Exper Pathol Pharmakol
{ 'DOI': '10.1007/s40121-020-00316-3', 'ISSN': ['2193-8229', '2193-6382'], 'URL': 'http://dx.doi.org/10.1007/s40121-020-00316-3', 'alternative-id': ['316'], 'assertion': [ { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'Received', 'name': 'received', 'order': 1, 'value': '2 June 2020'}, { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'First Online', 'name': 'first_online', 'order': 2, 'value': '8 July 2020'}], 'author': [ {'affiliation': [], 'family': 'Anderson', 'given': 'Danielle E.', 'sequence': 'first'}, {'affiliation': [], 'family': 'Sivalingam', 'given': 'Velraj', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kang', 'given': 'Adrian Eng Zheng', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Ananthanarayanan', 'given': 'Abhishek', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Arumugam', 'given': 'Harsha', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Jenkins', 'given': 'Timothy M.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hadjiat', 'given': 'Yacine', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Eggers', 'given': 'Maren', 'sequence': 'additional'}], 'container-title': 'Infectious Diseases and Therapy', 'container-title-short': 'Infect Dis Ther', 'content-domain': {'crossmark-restriction': False, 'domain': ['link.springer.com']}, 'created': {'date-parts': [[2020, 7, 8]], 'date-time': '2020-07-08T11:03:42Z', 'timestamp': 1594206222000}, 'deposited': { 'date-parts': [[2021, 7, 7]], 'date-time': '2021-07-07T23:25:07Z', 'timestamp': 1625700307000}, 'funder': [{'name': 'Mundipharma Singapore Holding Pte. Limited'}], 'indexed': {'date-parts': [[2024, 5, 7]], 'date-time': '2024-05-07T08:34:45Z', 'timestamp': 1715070885538}, 'is-referenced-by-count': 128, 'issue': '3', 'issued': {'date-parts': [[2020, 7, 8]]}, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2020, 9]]}}, 'language': 'en', 'license': [ { 'URL': 'https://creativecommons.org/licenses/by-nc/4.0', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 7, 8]], 'date-time': '2020-07-08T00:00:00Z', 'timestamp': 1594166400000}}, { 'URL': 'https://creativecommons.org/licenses/by-nc/4.0', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 7, 8]], 'date-time': '2020-07-08T00:00:00Z', 'timestamp': 1594166400000}}], 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-020-00316-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-020-00316-3/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-020-00316-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '297', 'original-title': [], 'page': '669-675', 'prefix': '10.1007', 'published': {'date-parts': [[2020, 7, 8]]}, 'published-online': {'date-parts': [[2020, 7, 8]]}, 'published-print': {'date-parts': [[2020, 9]]}, 'publisher': 'Springer Science and Business Media LLC', 'reference': [ { 'key': '316_CR1', 'unstructured': 'World Health Organisation. WHO Director-General’s opening remarks at the ' 'media briefing on COVID-19—11 March 2020: World Health Organisation. ' '2020. ' 'https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. ' 'Accessed 11 May 2020.'}, { 'DOI': '10.1016/j.ijid.2020.01.050', 'author': 'S Zhao', 'doi-asserted-by': 'publisher', 'first-page': '214', 'journal-title': 'Int J Infect Dis.', 'key': '316_CR2', 'unstructured': 'Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic ' 'reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 ' 'to 2020: a data-driven analysis in the early phase of the outbreak. Int ' 'J Infect Dis. 2020;92:214–7.', 'volume': '92', 'year': '2020'}, { 'key': '316_CR3', 'unstructured': 'Johns Hopkins University and Medicine. Coronavirus Resource Center: John ' 'Hopkins University. 2020. https://coronavirus.jhu.edu/map.html. Accessed ' '22 June 2020.'}, { 'DOI': '10.1016/bs.aivir.2018.01.001', 'author': 'VM Corman', 'doi-asserted-by': 'publisher', 'first-page': '163', 'journal-title': 'Adv Virus Res.', 'key': '316_CR4', 'unstructured': 'Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic ' 'human coronaviruses. Adv Virus Res. 2018;100:163–88.', 'volume': '100', 'year': '2018'}, { 'DOI': '10.1056/NEJMoa2001017', 'author': 'N Zhu', 'doi-asserted-by': 'publisher', 'first-page': '727', 'issue': '8', 'journal-title': 'N Engl J Med.', 'key': '316_CR5', 'unstructured': 'Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with ' 'pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.', 'volume': '382', 'year': '2020'}, { 'key': '316_CR6', 'unstructured': 'World Health Organisation. Interim recommendations on obligatory hand ' 'hygiene against transmission of COVID-19: World Health Organization. ' '2020. ' 'https://www.who.int/who-documents-detail/interim-recommendations-on-obligatory-hand-hygiene-against-transmission-of-covid-19. ' 'Accessed 18 Apr 2020.'}, { 'DOI': '10.1016/S2666-5247(20)30003-3', 'author': 'AWH Chin', 'doi-asserted-by': 'publisher', 'first-page': 'e10', 'journal-title': 'Lancet Microbe.', 'key': '316_CR7', 'unstructured': 'Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in ' 'different environmental conditions. Lancet Microbe. 2020;1:e10.', 'volume': '1', 'year': '2020'}, { 'DOI': '10.1007/s40121-017-0172-z', 'author': 'PM Vogt', 'doi-asserted-by': 'publisher', 'first-page': '545', 'issue': '4', 'journal-title': 'Infect Dis Ther.', 'key': '316_CR8', 'unstructured': 'Vogt PM, Hauser J, Mueller S, Bosse B, Hopp M. Efficacy of conventional ' 'and liposomal povidone-iodine in infected mesh skin grafts: an ' 'exploratory study. Infect Dis Ther. 2017;6(4):545–55.', 'volume': '6', 'year': '2017'}, { 'DOI': '10.1007/s40121-018-0200-7', 'author': 'M Eggers', 'doi-asserted-by': 'publisher', 'first-page': '249', 'issue': '2', 'journal-title': 'Infect Dis Ther.', 'key': '316_CR9', 'unstructured': 'Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal ' 'and virucidal efficacy of povidone-iodine gargle/mouthwash against ' 'respiratory and oral tract pathogens. Infect Dis Ther. 2018;7(2):249–59.', 'volume': '7', 'year': '2018'}, { 'key': '316_CR10', 'unstructured': 'World Health Organisation. WHO R&D Blueprint COVID 19 Experimental ' 'Treatments: World Health Organisation. 2020. ' 'https://www.who.int/docs/default-source/coronaviruse/covid-classification-of-treatment-types-rev.pdf. ' 'Accessed 18 May 2020.'}, { 'DOI': '10.1159/000246027', 'author': 'R Kawana', 'doi-asserted-by': 'publisher', 'first-page': '29', 'issue': 'Suppl 2', 'journal-title': 'Dermatology', 'key': '316_CR11', 'unstructured': 'Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human viruses ' 'by povidone-iodine in comparison with other antiseptics. Dermatology. ' '1997;195(Suppl 2):29–35.', 'volume': '195', 'year': '1997'}, { 'DOI': '10.1159/000089211', 'author': 'H Kariwa', 'doi-asserted-by': 'publisher', 'first-page': '119', 'issue': 'Suppl 1', 'journal-title': 'Dermatology', 'key': '316_CR12', 'unstructured': 'Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by ' 'means of povidone-iodine, physical conditions and chemical reagents. ' 'Dermatology. 2006;212(Suppl 1):119–23.', 'volume': '212', 'year': '2006'}, { 'DOI': '10.1007/s40121-015-0091-9', 'author': 'M Eggers', 'doi-asserted-by': 'publisher', 'first-page': '491', 'issue': '4', 'journal-title': 'Infect Dis Ther.', 'key': '316_CR13', 'unstructured': 'Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of ' 'povidone-iodine products against middle east respiratory syndrome ' 'coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA). Infect ' 'Dis Ther. 2015;4(4):491–501.', 'volume': '4', 'year': '2015'}, { 'author': 'C Spearman', 'first-page': '227', 'journal-title': 'Br J Psychol.', 'key': '316_CR14', 'unstructured': 'Spearman C. The method of ‘right and wrong cases’ (‘constant stimuli’) ' "without Gauss's formulae. Br J Psychol. 1908;2:227–42.", 'volume': '2', 'year': '1908'}, { 'DOI': '10.1007/BF01863914', 'author': 'G Kärber', 'doi-asserted-by': 'publisher', 'first-page': '480', 'journal-title': 'Archiv Exper Pathol Pharmakol.', 'key': '316_CR15', 'unstructured': 'Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer ' 'Reihenversuche. Archiv Exper Pathol Pharmakol. 1931;162:480–3.', 'volume': '162', 'year': '1931'}, { 'key': '316_CR16', 'unstructured': 'Comité Européen de Normalisation. EN14476:2013 + A1:2015: Chemical ' 'disinfectants and antiseptics. Quantitative suspension test for the ' 'evaluation of virucidal activity in the medical area. Test method and ' 'requirements (Phase 2/Step 1) 2015.'}, { 'author': 'M Cascella', 'key': '316_CR17', 'unstructured': 'Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, ' 'evaluation and treatment coronavirus (COVID-19). Treasure Island, FL: ' 'StatPearls; 2020.', 'volume-title': 'Features, evaluation and treatment coronavirus (COVID-19)', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.2565', 'author': 'Y Bai', 'doi-asserted-by': 'publisher', 'first-page': '1406', 'issue': '14', 'journal-title': 'JAMA', 'key': '316_CR18', 'unstructured': 'Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission ' 'of COVID-19. JAMA. 2020;323(14):1406–7.', 'volume': '323', 'year': '2020'}, { 'DOI': '10.3201/eid2607.200282', 'author': 'S Sanche', 'doi-asserted-by': 'publisher', 'first-page': '1470', 'issue': '7', 'journal-title': 'Emerg Infect Dis', 'key': '316_CR19', 'unstructured': 'Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High ' 'contagiousness and rapid spread of severe acute respiratory syndrome ' 'coronavirus 2. Emerg Infect Dis. 2020;26(7):1470–7.', 'volume': '26', 'year': '2020'}, { 'DOI': '10.1007/s40121-018-0202-5', 'author': 'M Eggers', 'doi-asserted-by': 'publisher', 'first-page': '235', 'issue': '2', 'journal-title': 'Infect Dis Ther.', 'key': '316_CR20', 'unstructured': 'Eggers M, Koburger-Janssen T, Ward LS, Newby C, Müller S. Bactericidal ' 'and virucidal activity of povidone-iodine and chlorhexidine gluconate ' 'cleansers in an in vivo hand hygiene clinical simulation study. Infect ' 'Dis Ther. 2018;7(2):235–47.', 'volume': '7', 'year': '2018'}, { 'key': '316_CR21', 'unstructured': 'Australian Dental Association. Managing COVID-19 Guidelines. 2020. ' 'https://www.ada.org.au/Covid-19-Portal/Cards/Dental-Profesionals/Guidelines-and-Risk-Factors/Just-an-information-Card. ' 'Accessed 21 June 2020.'}, { 'key': '316_CR22', 'unstructured': 'Centers for Disease Control and Prevention. Guidance for dental ' 'settings: interim infection prevention and control guidance for dental ' 'settings during the COVID-19 response: centers for disease control and ' 'prevention. 2020. ' 'https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html. ' 'Accessed 21 June 2020.'}, { 'DOI': '10.1159/000057722', 'author': 'T Nagatake', 'doi-asserted-by': 'publisher', 'first-page': '32', 'issue': 'Suppl 1', 'journal-title': 'Dermatology', 'key': '316_CR23', 'unstructured': 'Nagatake T, Ahmed K, Oishi K. Prevention of respiratory lnfections by ' 'povidone-lodine gargle. Dermatology. 2002;204(Suppl 1):32–6.', 'volume': '204', 'year': '2002'}, { 'DOI': '10.1038/s41586-020-2196-x', 'author': 'R Wölfel', 'doi-asserted-by': 'publisher', 'first-page': '465', 'issue': '7809', 'journal-title': 'Nature', 'key': '316_CR24', 'unstructured': 'Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of ' 'hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.', 'volume': '581', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(20)30196-1', 'author': 'KK To', 'doi-asserted-by': 'publisher', 'first-page': '565', 'issue': '5', 'journal-title': 'Lancet Infect Dis.', 'key': '316_CR25', 'unstructured': 'To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in ' 'posterior oropharyngeal saliva samples and serum antibody responses ' 'during infection by SARS-CoV-2: an observational cohort study. Lancet ' 'Infect Dis. 2020;20(5):565–74.', 'volume': '20', 'year': '2020'}, { 'author': 'D Gui', 'first-page': '3438', 'issue': '7', 'journal-title': 'Eur Rev Med Pharmacol Sci.', 'key': '316_CR26', 'unstructured': 'Gui D, Pepe G, Magalini S. Just one more hygiene practice in COVID-19. ' 'Eur Rev Med Pharmacol Sci. 2020;24(7):3438–9.', 'volume': '24', 'year': '2020'}, { 'DOI': '10.1093/function/zqaa002', 'author': 'VB O’Donnell', 'doi-asserted-by': 'publisher', 'first-page': 'zqaa002', 'journal-title': 'Function.', 'key': '316_CR27', 'unstructured': 'O’Donnell VB, Thomas D, Stanton R, et al. Potential role of oral rinses ' 'targeting the viral lipid envelope in SARS-CoV-2 infection. Function. ' '2020;1:zqaa002.', 'volume': '1', 'year': '2020'}, { 'DOI': '10.1016/j.oraloncology.2020.104724', 'author': 'LJ Mady', 'doi-asserted-by': 'publisher', 'first-page': '104724', 'journal-title': 'Oral Oncol.', 'key': '316_CR28', 'unstructured': 'Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. Consideration of ' 'povidone-iodine as a public health intervention for COVID-19: ' 'Utilization as "Personal Protective Equipment" for frontline providers ' 'exposed in high-risk head and neck and skull base oncology care. Oral ' 'Oncol. 2020;105:104724.', 'volume': '105', 'year': '2020'}, { 'DOI': '10.2139/ssrn.3563092', 'doi-asserted-by': 'publisher', 'key': '316_CR29', 'unstructured': 'Kirk-Bayley J, Challacombe S, Sunkaraneni S, Combes J. The use of ' 'povidone iodine nasal spray and mouthwash during the current COVID-19 ' 'pandemic may reduce cross infection and protect healthcare workers. ' '2020. https://doi.org/10.2139/ssrn.3563092.'}], 'reference-count': 29, 'references-count': 29, 'relation': { 'has-preprint': [ { 'asserted-by': 'object', 'id': '10.21203/rs.3.rs-34544/v1', 'id-type': 'doi'}, { 'asserted-by': 'object', 'id': '10.21203/rs.3.rs-34544/v2', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-020-00316-3'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus ' 'Causing COVID-19 Disease', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'volume': '9'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit